Cardioprotective and antihyperglycemic activity of vildagliptin in presence of nifedipine on adrenaline induced hyperglycemic rat

Generally there is higher prevalence of co-morbidity of diabetes and hypertension. Mortality increases more than 7 times when patient is having diabetes along with hypertension. In India 6.4% to 55% prevalence of hypertension among diabetes (Type 2) patients was found. Vildagliptin is an oral anti hyperglycemic agent of new class dipeptidyl peptidase-4 (DPP-4) inhibitor. Nifedipine is an antihypertensive drug that comes under the class of calcium channel blockers. The present study is to find out the effect of co administration of Nifedipine and Vildagliptin on cardioprotective and antihyperglycemic activity in adrenaline induced hyperglycemic rats. In acute and chronic condition study glucose level and lactate dehydrogenase (LDH) estimation in blood was done with the help of Glucometer and Lactate dehydrogenase assay kit respectively. Albino Rats heart muscles were subjected to histopathological examination. After co-administration of drugs initial glucose level (142.77 ± 12.9 mg/dl) and final blood glucose level (135.1 ± 48.7 mg/dl) in acute condition and initial glucose level (160.2 ± 9.3 mg/dl) and final blood glucose level (154.6 ±14.8 mg/dl) in chronic condition were found. In chronic condition initial LDH level (455.9 ±17.1 IU/L) and final LDH level (236 ±24.1 IU/L) in blood were found. In microscopic examination of endocardium layer of adrenaline induced hyperglycemic rats treated with co-administration of drugs necrosis was not found, it confirms their cardioprotective activity. On the basis of study conclusion was that when co-administration of Nifedipine and Vildagliptin, nifedipine significantly reducing the antihyperglycemic activity but it has no markedly effect on cardioprotective activity. Keywords: Vildagliptin, Nifedipine, Lactate dehydrogenase, Dipeptidyl peptidase-4 inhibitor